Last reviewed · How we verify
efgartigimod PH20 SC in stage B
At a glance
| Generic name | efgartigimod PH20 SC in stage B |
|---|---|
| Sponsor | argenx |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis (PHASE3)
- A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (PHASE2)
- Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- efgartigimod PH20 SC in stage B CI brief — competitive landscape report
- efgartigimod PH20 SC in stage B updates RSS · CI watch RSS
- argenx portfolio CI